Incorporating Targeted Agents Into Future Therapy of Chronic Lymphocytic Leukemia

Seminars in Hematology

Volumn 51, Issue 3, 2014, Pages 235-248

  Pallasch, Christian P ^a   Hallek, Michael ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; B LYMPHOCYTE RECEPTOR; BRUTON TYROSINE KINASE; CHIMERIC ANTIGEN RECEPTOR; CYCLIN DEPENDENT KINASE; IBRUTINIB; IDELALISIB; IMMUNOMODULATING AGENT; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY; OBINUTUZUMAB; OFATUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; PROTEIN BCL 2; PROTEIN BCL 2 INHIBITOR; PROTEIN INHIBITOR; PROTEIN KINASE SYK; RITUXIMAB; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER PATIENT; CANCER PROGNOSIS; CHRONIC LYMPHATIC LEUKEMIA; DIARRHEA; DISEASE ACTIVITY; DISEASE COURSE; DRUG CYTOTOXICITY; DRUG ERUPTION; DRUG TARGETING; ENZYME INHIBITION; FATIGUE; FEVER; HIGH RISK PATIENT; HUMAN; IMMUNOMODULATION; INDUCTION CHEMOTHERAPY; INFECTION; LEUKEMIA CELL; LEUKEMOGENESIS; MAINTENANCE THERAPY; NEUTROPENIA; NONHUMAN; PHARMACEUTICAL CARE; PRIORITY JOURNAL; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME; UPPER RESPIRATORY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; CELL- AND TISSUE-BASED THERAPY; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PROTEIN KINASE INHIBITORS; RECOMBINANT FUSION PROTEINS;

EID: 84904408532     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2014.05.005     Document Type: Article

References (109)

1. Cramer P., Hallek M. Prognostic factors in chronic lymphocytic leukemia-what do we need to know?. Nature Rev Clin Oncol 2011, 8:38-47.
2. Mayr C., Speicher M.R., Kofler D.M., et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 2006, 107:742-751.
3. Calin G.A., Dumitru C.D., Shimizu M., et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002, 99:15524-15529.
4. Zenz T., Mertens D., Kuppers R., et al. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nature Rev Cancer 2010, 10:37-50.
5. Puente X.S., Pinyol M., Quesada V., et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011, 475:101-105.
6. Quesada V., Conde L., Villamor N., et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2012, 44:47-52.
7. Wang L., Lawrence M.S., Wan Y., et al. SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia. New Engl J Med 2011, 365:2497-2506.
8. Rossi D., Rasi S., Spina V., et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 2013, 121:1403-1412.
9. Burger J.A., Ghia P., Rosenwald A., Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009, 114:3367-3375.
10. Zhang W., Trachootham D., Liu J., et al. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nature Cell Biol 2012, 14:276-286.
11. Lutzny G., Kocher T., Schmidt-Supprian M., et al. Protein kinase c-beta-dependent activation of NF-kappaB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo. Cancer Cell 2013, 23:77-92.
12. Agathangelidis A., Darzentas N., Hadzidimitriou A., et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood 2012, 119:4467-4475.
13. Axelrod O., Silverman G.J., Dev V., et al. Idiotypic cross-reactivity of immunoglobulins expressed in Waldenstrom's macroglobulinemia, chronic lymphocytic leukemia, and mantle zone lymphocytes of secondary B-cell follicles. Blood 1991, 77:1484-1490.
14. Herve M., Xu K., Ng Y.S., et al. Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J Clin Invest 2005, 115:1636-1643.
15. Mockridge C.I., Potter K.N., Wheatley I., et al. Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood 2007, 109:4424-4431.
16. Stamatopoulos K., Belessi C., Moreno C., et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood 2007, 109:259-270.
17. Murray F., Darzentas N., Hadzidimitriou A., et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood 2008, 111:1524-1533.
18. Mecklenbrauker I., Kalled S.L., Leitges M., Mackay F., Tarakhovsky A. Regulation of B-cell survival by BAFF-dependent PKCdelta-mediated nuclear signalling. Nature 2004, 431:456-461.
19. Stevenson F.K., Krysov S., Davies A.J., Steele A.J., Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2011, 118:4313-4320.
20. Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2012, 88-96.
21. Young R.M., Staudt L.M. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nature Rev Drug Disc 2013, 12:229-243.
22. Isfort S., Cramer P., Hallek M. Novel and emerging drugs for chronic lymphocytic leukemia. Curr Cancer Drug Targets 2012, 12:471-483.
23. Huhn D., von Schilling C., Wilhelm M., et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001, 98:1326-1331.
24. O'Brien S., Kantarijan H., Thomas D., et al. Rituximab dose-escalation trial in chronic lymphocytic leukaemia. J Clin Oncol 2001, 19:2165-2170.
25. Bauer K., Rancea M., Roloff V., et al. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia. Cochrane Database Syst Rev 2012, (11):CD008079.
26. Cang S., Mukhi N., Wang K., Liu D. Novel CD20 monoclonal antibodies for lymphoma therapy. J Hematol Oncol 2012, 5:64.
27. Maloney D.G. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med 2012, 366:2008-2016.
28. Wierda W.G., Kipps T.J., Mayer J., et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010, 28:1749-1755.
29. Patz M., Isaeva P., Forcob N., et al. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol 2011, 152:295-306.
30. Mossner E., Brunker P., Moser S., et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010, 115:4393-4402.
31. Morschhauser F., Cartron G., Lamy T., et al. Phase I Study of RO5072759 (GA101) in relapsed/refractory chronic lymphocytic leukemia. ASH Annual Meeting Abstracts 2009, 114:884.
32. Goede V., Fischer K., Busch R., et al. Obinutuzumab plus chlorambucil in patients with cll and coexisting conditions. N Engl J Med 2014, 370:1101-1120.
33. Österborg A., Dyer M.J., Bunjes D., et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leucemia. European study group of CAMPATH-1H treatment in chronic lymphocytic leukemia. J Clin Oncol 1997, 15:1567-1574.
34. Rai K.R., Freter C.E., Mercier R.J., et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002, 20:3891-3897.
35. Keating M.J., Flinn I., Jain V., et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002, 99:3554-3561.
36. Stilgenbauer S., Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 2002, 347:452-453.
37. Lozanski G., Heerema N.A., Flinn I.W., et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004, 103:3278-3281.
38. Hillmen P., Skotnicki A.B., Robak T., et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007, 25:5616-5623.
39. Sher T., Miller K.C., Lawrence D., et al. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma 2010, 51:85-88.
40. Moutouh-de Parseval L.A., Weiss L., DeLap R.J., Knight R.D., Zeldis J.B. Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia. J Clin Oncol 2007, 25:5047.
41. Chanan-Khan A., Miller K.C., Musial L., et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006, 24:5343-5349.
42. Ferrajoli A., Lee B.N., Schlette E.J., et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008, 111:5291-5297.
43. Chanan-Khan A.A., Czuczman M.S., Padmanabhan S., et al. Clinical efficacy of lenalidomide in fludarabine-refractory chronic lymphocytic leukemia patients. ASH Annual Meeting Abstracts 2007, 110:3108.
44. Badoux X.C., Keating M.J., Wen S., et al. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2013, 31:584-591.
45. Brown J.R., Abramson J., Hochberg E., et al. A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL. Leukemia 2010, 24:1972-1975.
46. Flinn I.W., Berdeja J.G., Waselenko J.K., et al. Preliminary results from a Phase I/II study of fludarabine, rituximab, and lenalidomide in untreated patients with chronic lymphocytic leukemia (CLL). ASH Annual Meeting Abstracts 2010, 116:2461.
47. Egle A., Steurer M., Melchardt T., Stoll M., Greil R. The REVLIRIT CLL5 AGMT Study-a Phase I/II trial combining fludarabine/rituximab with escalating doses of lenalidomide followed by rituximab/lenalidomide in untreated chronic lymphocytic leukemia (CLL): results of a planned interim analysis. ASH Annual Meeting Abstracts 2009, 114:3453.
48. Blum K.A., Jones J.A., Andritsos L., et al. Phase 1 trial of flavopiridol and lenalidomide in patients with previously treated chronic lymphocytic leukemia (CLL). ASH Annual Meeting Abstracts 2010, 116:2472.
49. Badoux X., O'Brien S., Wierda W.G., et al. Combination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia: initial results of a Phase II Trial. ASH Annual Meeting Abstracts 2010, 116:2464.
50. Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011, 365:725-733.
51. Porter D.L., Grupp S.A., Kalos M., et al. Chimeric antigen receptor T cells directed against cd19 induce durable responses and transient cytokine release syndrome in relapsed, refractory CLL and ALL. ASH Annual Meeting Abstracts 2012, 120:717.
52. Okkenhaug K., Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nature Rev Immunol 2003, 3:317-330.
53. Hoellenriegel J., Meadows S.A., Sivina M., et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011, 118:3603-3612.
54. Brown J.R., Furman R.R., Flinn I.W., et al. Final results of a phase 1 study of idelalisib (GS-1101): a selective inhibitor of phosphatidylinositol 3-kinase p110 delta (PI3Kdelta) in patients with relapsed or refractory CLL. J Clin Oncol 2013, 31. (Abstract 7003).
55. O'Brien S.M., Lamanna N., Kipps T.J., et al. A phase 2 study of the selective phosphatidylinositol 3-kinase delta (PI3Kdelta) inhibitor idelalisib (GS-1101) in combination with rituximab in treatment-naïve patients ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). J Clin Oncol 2013, 31(Suppl). (Abstract).
56. Furman R.R., Sharman J.P., Coutre S.E., et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014, 370:997-1007.
57. Herman S.E., Gordon A.L., Hertlein E., et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011, 117:6287-6296.
58. Advani R.H., Buggy J.J., Sharman J.P., et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013, 31:88-94.
59. Byrd J.C., Furman R.R., Coutre S.E., et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013, 369:32-42.
60. Friedberg J.W., Sharman J., Sweetenham J., et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010, 115:2578-2585.
61. Johnson A.J., Yeh Y.Y., Smith L.L., et al. The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells. Leukemia 2012, 26:2554-2557.
62. Kruse U., Pallasch C.P., Bantscheff M., et al. Chemoproteomics-based kinome profiling and target deconvolution of clinical multi-kinase inhibitors in primary chronic lymphocytic leukemia cells. Leukemia 2011, 25:89-100.
63. Tong W.G., Chen R., Plunkett W., et al. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. J Clin Oncol 2010, 28:3015-3022.
64. Chao D.T., Korsmeyer S.J. BCL-2 family: regulators of cell death. Annu Rev Immunol 1998, 16:395-419.
65. Tsujimoto Y., Finger L.R., Yunis J., Nowell P.C., Croce C.M. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 1984, 226:1097-1099.
66. Roberts A.W., Seymour J.F., Brown J.R., et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012, 30:488-496.
67. Souers A.J., Leverson J.D., Boghaert E.R., et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nature Med 2013, 19:202-208.
68. Seymour J., Davids M., Pagel J., et al. Updated results of a Phase I first-in-human study of the BCL-2 Inhibitor ABT-199 (GDC-0199) in patients with relapsed/ refractory (R/R) chronic lymphocytic leukaemia (CLL). Hematol Oncol 2013, 31:115. (Abstract 057).
69. Chemotherapeutic options in chronic lymphocytic leukemia. J Natl Cancer Inst 1999, 91:861-868. CLL Trialists Collaborative Group.
70. Hallek M., Schmitt B., Wilhelm M., et al. Fludarabine plus cyclophosphamide for the treatment of chronic lymphocytic leukemia: results of a phase II study (CLL2 protocol) of the German CLL Study Group (GCLLSG). Br J Haematol 2001, 114:342-348.
71. Hallek M., Fischer K., Fingerle-Rowson G., et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010, 376:1164-1174.
72. Knauf W.U., Lissichkov T., Aldaoud A., et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009, 27:4378-4384.
73. Steurer M., Pall G., Richards S., et al. Purine antagonists for chronic lymphocytic leukaemia. Cochrane Database Syst Rev 2006, (3):CD004270.
74. Johnson S., Smith A.G., Loffler H., et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 1996, 347:1432-1438.
75. Rai K.R., Peterson B.L., Appelbaum F.R., et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000, 343:1750-1757.
76. Leporrier M., Chevret S., Cazin B., et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001, 98:2319-2325.
77. Robak T., Blonski J.Z., Kasznicki M., et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000, 96:2723-2729.
78. Hallek M., Pflug N. State of the art treatment of chronic lymphocytic leukaemia. Blood Rev 2011, 25:1-9.
79. Tam C.S., O'Brien S., Wierda W., et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008, 112:975-980.
80. Robak T., Dmoszynska A., Solal-Celigny P., et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010, 28:1756-1765.
81. Foon K.A., Boyiadzis M., Land S.R., et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009, 27:498-503.
82. Parikh S.A., Keating M.J., O'Brien S., et al. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood 2011, 118:2062-2068.
83. Bosch F., Abrisqueta P., Villamor N., et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol 2009, 27:4578-4584.
84. Reynolds C., Di Bella N., Lyons R.M., et al. A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. Invest New Drugs 2012, 30:1232-1240.
85. Fischer K., Cramer P., Busch R., et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011, 29:3559-3566.
86. Fischer K., Cramer P., Busch R., et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2012, 30:3209-3216.
87. Kennedy B., Rawstron A., Carter C., et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 2002, 99:2245-2247.
88. Elter T., Borchmann P., Schulz H., et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005, 23:7024-7031.
89. Lepretre S., Aurran T., Mahe B., et al. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood 2012, 119:5104-5110.
90. Elter T., Gercheva-Kyuchukova L., Pylylpenko H., et al. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. Lancet Oncol 2011, 12:1204-1213.
91. Pettitt A.R., Jackson R., Carruthers S., et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the National Cancer Research Institute CLL206 trial. J Clin Oncol 2012, 30:1647-1655.
92. Stilgenbauer S., Cymbalista F., Leblond V., et al. Alemtuzumab plus oral dexamethasone, followed by alemtuzumab maintenance or allogeneic transplantation in ultra high-risk CLL: updated results from a phase ii study of the Gcllsg and fcgcll/MW. ASH Annual Meeting Abstracts 2012, 120:716.
93. Furman R.R., Sharman J.P., Coutre S.E., et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014, 370:997-1007.
94. Brown J.R., Levine R.L., Thompson C., et al. Systematic genomic screen for tyrosine kinase mutations in CLL. Leukemia 2008, 22:1966-1969.
95. Bottcher S., Hallek M., Ritgen M., Kneba M. The role of minimal residual disease measurements in the therapy for CLL: is it ready for prime time?. Hematol Oncol Clin North Am 2013, 27:267-288.
96. Landau D.A., Carter S.L., Stojanov P., et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013, 152:714-726.
97. Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Blood 2013, 122:3723-3734.
98. Furman R.R., Forero-Torres A., Shustov A., Drachman J.G. A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2010, 51:228-235.
99. Byrd J.C., Kipps T.J., Flinn I.W., et al. Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leuk Lymphoma 2012, 53:2136-2142.
100. Castro J.E., Melo-Cardenas J., Urquiza M., et al. Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule. Cancer Res 2012, 72:2937-2948.
101. Awan F.T., Pagel J.M., Andritsos L.A., et al. Phase 1 Study of Tru-016, an anti-CD37 SMIP protein in naive and relapsed and/or refractory CLL patients. ASH Annual Meeting Abstracts 2011, 118:1792.
102. O'Brien S.M., Claxton D.F., Crump M., et al. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 2009, 113:299-305.
103. Amrein P.C., Attar E.C., Takvorian T., et al. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 2011, 17:2977-2986.
104. Phelps M.A., Lin T.S., Johnson A.J., et al. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 2009, 113:2637-2645.
105. Flynn J.M., Jones J.A., Andritsos L., et al. Update on the phase i study of the cyclin dependent kinase inhibitor dinaciclib (SCH 727965) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): confirmation of clinical activity and feasibility of long-term administration. ASH Annual Meeting Abstracts 2010, 116:1396.
106. Zent C.S., LaPlant B.R., Johnston P.B., et al. The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer 2010, 116:2201-2207.
107. Decker T., Sandherr M., Goetze K., et al. A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL. Ann Hematol 2009, 88:221-227.
108. Dühren-von Minden M., Übelhart R., Schneider D., et al. Chronic lympho cytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 2012, 489:309-312.
109. Pallasch C.P., Leskov I., Braun C.J., et al. Sensitizing protective tumor microenvironments to antibody-mediated therapy. Cell 2014, 156:590-602.